Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on December 12, 2022, regarding events occurring on December 7 and December 8, 2022. The filing addresses significant changes in the company's executive leadership, specifically within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes.
Material Changes
- Departure of CFO: Michael Rossi resigned as Chief Financial Officer and Treasurer, effective December 31, 2022. He will remain with the company until May 10, 2023, to assist with the transition.
- Appointment of Interim CFO: Jennifer Cote was appointed as Interim Chief Financial Officer and Treasurer, effective upon Mr. Rossi's resignation. She will also serve as the principal financial officer and principal accounting officer.
- Compensation: The terms of Ms. Cote's compensation arrangements have not been finalized; an amendment to this filing will be submitted once terms are set.
Outlook, Risks, and Management Commentary
The filing notes that a press release was issued on December 12, 2022, to publicly announce these leadership changes. No specific guidance, outlook, or risk factors related to financial performance were disclosed in this report. The primary operational risk highlighted is the transition of financial leadership.
Investor Verification Checklist
- Verify the finalized compensation terms for Interim CFO Jennifer Cote in the upcoming amendment to this Form 8-K.
- Monitor the transition timeline to ensure continuity of financial reporting through May 10, 2023.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership change.